Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + vedicetumab perioperative therapy for locally advanced upper tract urothelial carcinoma
ChiCTR2300067836Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and disitamab vedotin in upper tract urothelial carcinoma (UTUC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
tislelizumabdisitamab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2300067836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067836.